Effect of early membrane removal on the treatment of mandibular class II furcation defects--a controlled clinical trial with re-entry after 12 months.

In a previous study in dogs, the early removal of expanded polytetrafluoroethylene (ePTFE) membrane (2 weeks after placement) showed histomorphometric results (of new bone, cementum and periodontal ligament) similar to that obtained with membrane removal at 4 weeks after placement. This study evaluated the influence of early removal of an ePTFE membrane on the treatment of Class II furcation defects. Twelve patients who provided 12 pairs of mandibular furcation defects were recruited for the study. Baseline clinical measurements were recorded: plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), gingival margin position (GMP) and relative clinical attachment level (RCAL). Full flaps were elevated and hard tissue measurements were performed during the surgery: relative vertical (RVBL) and horizontal (RHBL) bone level. The ePTFE membranes were adapted and sutured to their correspondent tooth and removed at 2 weeks in the test group (TGr) and at 4 weeks in the control group (CGr). After 1 year all sites were re-entered, and soft and hard tissue measurements were recorded. There were no statistically significant differences between TGr and CGr for any baseline measurement. After 12 months, there were no statistically significant differences between TGr and CGr in the PD (p=0.74), GMP (p=0.76) and RCAL (p=0.44) values. However, the RHBL resolution was significant for both groups (CGr p=0.01 and TGr p=0.02), without difference between groups (p=0.39). Early removal of membranes did not affect the outcome on the treatment of Class II furcation defects.

Effect of Early Membrane Removal on the Treatment of Mandibular Class II Furcation Defects - A Controlled Clinical Trial with Re-entry after 12 Months

In a previous study in dogs, the early removal of expanded polytetrafluoroethylene (ePTFE) membrane (2 weeks after placement) showed histomorphometric results (of new bone, cementum and periodontal ligament) similar to that obtained with membrane removal at 4 weeks after placement. This study evaluated the influence of early removal of an ePTFE membrane on the treatment of Class II furcation defects. Twelve patients who provided 12 pairs of mandibular furcation defects were recruited for the study. Baseline clinical measurements were recorded: plaque index (PI), gingival index (GI), bleeding on probing (BOP), probing depth (PD), gingival margin position (GMP) and relative clinical attachment level (RCAL). Full flaps were elevated and hard tissue measurements were performed during the surgery: relative vertical (RVBL) and horizontal (RHBL) bone level. The ePTFE membranes were adapted and sutured to their correspondent tooth and removed at 2 weeks in the test group (TGr) and at 4 weeks in the control group (CGr). After 1 year all sites were re-entered, and soft and hard tissue measurements were recorded. There were no statistically significant differences between TGr and CGr for any baseline measurement. After 12 months, there were no statistically significant differences between TGr and CGr in the PD (p=0.74), GMP (p=0.76) and RCAL (p=0.44) values. However, the RHBL resolution was significant for both groups (CGr p=0.01 and TGr p=0.02), without difference between groups (p=0.39). Early removal of membranes did not affect the outcome on the treatment of Class II furcation defects.

Em estudo prévio, em cães, a remoção precoce da membrana de politetrafluoretileno expandido (PTFE-e), 2 semanas após a colocação, mostrou resultados histomorfométricos (formação de novo osso, cemento e ligamento periodontal) similares aos de remoção da membrana 4 semanas após a sua colocação. Este estudo avaliou a influência da remoção precoce de uma membrana de PTFE-e no tratamento de defeitos de bifurcação classe II. Foram selecionados para o estudo 12 pacientes, com 12 pares de defeitos de bifurcação mandibulares. Foram feitas as seguintes medidas clínicas iniciais: índice de placa (IP), índice gingival (IG), sangramento à sondagem (SAS), profundidade de sondagem (PS), posição da margem gingival (PMG) e nível relativo da inserção clínica (NRIC). Foram elevados retalhos totais e as medidas do tecido ósseo foram tomadas transcirurgicamente: níveis ósseos vertical (NOV) e horizontal (NOH). Membranas de PTFE-e foram adaptadas e suturadas aos dentes correspondentes e removidas após 2 semanas no grupos teste (GT) ou quatro semanas no grupo controle (GC). Após 1 ano, em todos os sites foi realizada reentrada cirúrgica e medidas clínicas e ósseas foram novamente feitas. Não houve diferenças estatisticamente significantes entre GT e GC para nenhuma das medidas iniciais avaliadas. Após 12 meses, não houve diferenças estatisticamente significantes entre GT e GC para os valores de PS (p=0,74), PMG (p=0,76) e NRIC (p=0,44). Entretanto, a resolução do nível ósseo horizontal foi significante para ambos os grupos (GC: p=0,01 e GT: p=0,02), sem diferenças entre grupos (p=0,39). A remoção precoce da membrana não afetou os resultados do tratamento de defeitos de bifurcação Classe II.

Effects of periodontal therapy on glycemic control and inflammatory markers.

BACKGROUND: Periodontitis, a complication of diabetes mellitus (DM), can induce or perpetuate systemic conditions. This double-masked, placebo-controlled study evaluated the effects of periodontal therapy (scaling and root planing [SRP]) on the serum levels of glycated hemoglobin (HbA1c) and on inflammatory biomarkers. METHODS: Thirty subjects with type 2 DM and periodontitis were treated with SRP + placebo (SRP; N = 15) or with SRP + doxycycline (SRP+Doxy; N = 15), 100 mg/day, for 14 days. Clinical and laboratory data were recorded at baseline and at 3 months after treatment. RESULTS: After 3 months, the reduction in probing depth was 0.8 mm for the SRP group (P <0.01) and 1.1 mm for the SRP+Doxy group (P <0.01) followed by a 0.9% (SRP; P = 0.17) and 1.5% (SRP+Doxy; P <0.01) reduction in HbA1c levels. A significant reduction in interleukin (IL)-6; interferon-inducible protein 10; soluble fas ligand; granulocyte colony-stimulating factor; RANTES; and IL-12 p70 serum levels were also verified (N = 30). To our knowledge, this is the first report on the effects of periodontal therapy on multiple systemic inflammatory markers in DM. CONCLUSIONS: Periodontal therapy may influence the systemic conditions of patients with type 2 DM, but no statistical difference was observed with the adjunctive systemic doxycycline therapy. Moreover, it is possible that the observed improvement in glycemic control and in the reduction of inflammatory markers could also be due to diet, which was not controlled in our study. Therefore, a confirmatory study with a larger sample size and controlled diet is necessary.